Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel F Martin

Showing results (71-80 of 116) with videos related to

Pageof 12
Sort By:
Ophthalmology|May 10, 2016
Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials, Maureen G Maguire, Daniel F Martin, et al.
Ophthalmology|April 1, 2015
Influence of the Vitreomacular Interface on Treatment Outcomes in the Comparison of Age-Related Macular Degeneration Treatments TrialsThomas A Ciulla, Thomas A Cuilla, Gui-Shuang Ying, et al.
JAMA Ophthalmology|January 31, 2020
Characteristics of Eyes With Good Visual Acuity at 5 Years After Initiation of Treatment for Age-Related Macular Degeneration but Not Receiving Treatment From Years 3 to 5: Post Hoc Analysis of the CATT Randomized Clinical TrialDrew Scoles, Gui-Shuang Ying, Wei Pan, et al.
Canadian Journal of Ophthalmology. Journal Canadien D'Ophtalmologie|June 1, 2025
Association of changes in optical coherence tomography metrics with changes in refractive error in patients with neovascular age-related macular degeneration in the CATTMatthew R Starr, Eric A Lovett, Rachel Israilevich, et al.
JCI Insight|November 2, 2023
A CD6-targeted antibody-drug conjugate as a potential therapy for T cell-mediated disordersLingjun Zhang, Liping Luo, Jin Y Chen, et al.
Ophthalmology Science|May 11, 2026
Diabetic Retinopathy Severity on Ultra-Widefield Fluorescein Angiography versus Color Photography and Association with Risk of Disease WorseningPaolo S Silva, Danni Liu, Lloyd P Aiello, et al.
Ophthalmology. Retina|June 14, 2021
Predominantly Persistent Subretinal Fluid in the Comparison of Age-Related Macular Degeneration Treatments TrialsJason Q Core, Maxwell Pistilli, Ebenezer Daniel, et al.
Ophthalmology|January 13, 2017
Incidence and Growth of Geographic Atrophy during 5 Years of Comparison of Age-Related Macular Degeneration Treatments TrialsJuan E Grunwald, Maxwell Pistilli, Ebenezer Daniel, et al.
Ophthalmology. Retina|April 11, 2022
Predominantly Persistent Intraretinal Fluid in the Comparison of Age-related Macular Degeneration Treatments TrialsJason Q Core, Maxwell Pistilli, Peiying Hua, et al.
American Journal of Ophthalmology|November 22, 2020
Localized Optical Coherence Tomography Precursors of Macular Atrophy and Fibrotic Scar in the Comparison of Age-Related Macular Degeneration Treatments TrialsAvni P Finn, Maxwell Pistilli, Vincent Tai, et al.
Pageof 12

Showing results (71-80 of 116) with videos related to

Sort By:
Pageof 12
Ophthalmology|May 10, 2016
Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials, Maureen G Maguire, Daniel F Martin, et al.
Ophthalmology|April 1, 2015
Influence of the Vitreomacular Interface on Treatment Outcomes in the Comparison of Age-Related Macular Degeneration Treatments TrialsThomas A Ciulla, Thomas A Cuilla, Gui-Shuang Ying, et al.
JAMA Ophthalmology|January 31, 2020
Characteristics of Eyes With Good Visual Acuity at 5 Years After Initiation of Treatment for Age-Related Macular Degeneration but Not Receiving Treatment From Years 3 to 5: Post Hoc Analysis of the CATT Randomized Clinical TrialDrew Scoles, Gui-Shuang Ying, Wei Pan, et al.
Canadian Journal of Ophthalmology. Journal Canadien D'Ophtalmologie|June 1, 2025
Association of changes in optical coherence tomography metrics with changes in refractive error in patients with neovascular age-related macular degeneration in the CATTMatthew R Starr, Eric A Lovett, Rachel Israilevich, et al.
JCI Insight|November 2, 2023
A CD6-targeted antibody-drug conjugate as a potential therapy for T cell-mediated disordersLingjun Zhang, Liping Luo, Jin Y Chen, et al.
Ophthalmology Science|May 11, 2026
Diabetic Retinopathy Severity on Ultra-Widefield Fluorescein Angiography versus Color Photography and Association with Risk of Disease WorseningPaolo S Silva, Danni Liu, Lloyd P Aiello, et al.
Ophthalmology. Retina|June 14, 2021
Predominantly Persistent Subretinal Fluid in the Comparison of Age-Related Macular Degeneration Treatments TrialsJason Q Core, Maxwell Pistilli, Ebenezer Daniel, et al.
Ophthalmology|January 13, 2017
Incidence and Growth of Geographic Atrophy during 5 Years of Comparison of Age-Related Macular Degeneration Treatments TrialsJuan E Grunwald, Maxwell Pistilli, Ebenezer Daniel, et al.
Ophthalmology. Retina|April 11, 2022
Predominantly Persistent Intraretinal Fluid in the Comparison of Age-related Macular Degeneration Treatments TrialsJason Q Core, Maxwell Pistilli, Peiying Hua, et al.
American Journal of Ophthalmology|November 22, 2020
Localized Optical Coherence Tomography Precursors of Macular Atrophy and Fibrotic Scar in the Comparison of Age-Related Macular Degeneration Treatments TrialsAvni P Finn, Maxwell Pistilli, Vincent Tai, et al.
Pageof 12